Clinical Trials Browser

Phase 2/3 × INDUSTRY × Decitabine × Clear all

NCT02472145 2019-03-19

An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Phase 2/3 Completed

326 enrolled 20 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute